SWOG S0518: phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127) - Yao, J; Guthrie, K; Moran, C (2015)
33(suppl):abstr 4004